From our early studies, we have observed that an increased level of plasma HER2/neu in both African-American and Latina women with breast cancer who underwent surgery and completed chemotherapy was associated with poor outcome and a reduction in disease-free survival (DFS) [3]. The gene discussed is ERBB2; the disease is breast carcinoma.